Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory
Not Applicable
- Conditions
- Early Stage Breast Cancer (Stage 0-III)
- Interventions
- Other: Exercise Regimen
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Nevada Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT01157130
- Locations
- ๐บ๐ธ
Nevada Cancer Institute, Las Vegas, Nevada, United States
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Phase 2
Withdrawn
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Nevada Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT01131247
- Locations
- ๐บ๐ธ
Mayo Clinic, PHoenix/Scottsdale, Arizona, United States
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
Phase 2
Terminated
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Nevada Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT01125787
- Locations
- ๐บ๐ธ
Nevada Cancer Institute, Las Vegas, Nevada, United States
๐บ๐ธUniversity of Florida, Gainesville, Florida, United States
5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Nevada Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT00886457
- Locations
- ๐บ๐ธ
Nevada Cancer Institute, Las Vegas, Nevada, United States
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
- First Posted Date
- 2009-04-14
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Nevada Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT00880867
- Locations
- ๐บ๐ธ
Nevada Cancer Institute, Las Vegas, Nevada, United States
Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer
Phase 1
Terminated
- Conditions
- Non-Small Cell Lung Cancer and Pleural Mesothelioma
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- Nevada Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00281125
- Locations
- ๐บ๐ธ
Nevada Cancer Institute, Las Vegas, Nevada, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath